BioSpace News Archive

Business

Record-breaking $11.2 million raised for St. Jude Children’s Research Hospital® at 17th annual St. Jude Memphis Marathon® Weekend

In its biggest year yet, St. Jude Memphis Marathon® Weekend presented by Juice Plus+® raised a record $11.2 million for kids at St. Jude Children’s Research Hospital®.

December 2, 2018
·
4 min read
Drug Development

bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting

bb21217 early safety profile consistent with CAR T platform therapies

December 2, 2018
·
10 min read
Drug Development

Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R2) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018

Pivotal phase 3 data show investigational R2 significantly extended progression-free survival compared with rituximab plus placebo

December 2, 2018
·
18 min read
Drug Development

Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders

All five patients with inherited metabolic disorders (IMDs) treated with MGTA-456 in ongoing Phase 2 study met the primary endpoint of successful engraftment

December 2, 2018
·
9 min read
Drug Development

Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit

Magenta Therapeutics today announced that the Company presented preclinical research on its targeted conditioning programs at the 60th annual meeting of the American Society of Hematology (ASH).

December 2, 2018
·
9 min read
BioForest

Finnish Blood Testing Scale-up and Health Service Provider Introduce Healthcare for the 21st Century - Connecting Molecular Medicine With Lifestyle Habits

The new service, Virta 360, connects a person’s current state of physical health with their lifestyle. The service helps people to understand their current risks for chronic diseases and identifies potential areas where they can improve their wellbeing.

December 2, 2018
·
3 min read
BerGenBio Reports 43% Response Rate With Bemcentinib Monotherapy in AXL Positive R/R AML/MDS Patients at ASH

43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6 out of 14)

December 2, 2018
·
5 min read
Policy

European Medicines Agency Accepts Extension Marketing Authorisation Application for Review of Celltrion’s Remsima SC, the Subcutaneous Version of Remsima®

European Medicines Agency started to officially review ‘Remsima SC’; expecting European approval in the second half of next year

December 2, 2018
·
2 min read
Drug Development

Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH

Overall response rate (ORR) of 61% and complete response (CR) rate of 28% in 74 patients with indolent non-Hodgkin’s lymphoma (iNHL)

December 2, 2018
·
8 min read